NCT02448290View on ClinicalTrials.gov

Single-arm Study of Selumetinib in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With Low/High MEK Signature, RAS Mutation or RAS Amplification as a Second-line Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 12, 2014

Primary Completion Date

May 17, 2018

Study Completion Date

May 17, 2018

Conditions
Gastric Adenocarcinoma
Interventions
DRUG

docetaxel plus selumetinib

Selumetinib will be administered orally 75mg twice a day continuously. Docetaxel will be administered as an IV infusion over 1 hour at 60 mg/m2 every 3 week of a 21 days schedule.

Trial Locations (1)

135-710

Samsung Medical center, Seoul

All Listed Sponsors
lead

Samsung Medical Center

OTHER

NCT02448290 - Single-arm Study of Selumetinib in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With Low/High MEK Signature, RAS Mutation or RAS Amplification as a Second-line Chemotherapy | Biotech Hunter | Biotech Hunter